Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

57

Enrollment

OTHER

Sponsor class

Stopped Permanent closure of trial to further accrual based on IDE disapproval

Conditions

Prostate Cancer

Interventions

DRUG: Nilutamide
DRUG: Dasatinib

Sponsor

Duke University

Collaborators

[object Object]